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Background
Activation of tumor antigen-specific T-cell responses and
bypass/neutralization of tumor immune tolerance
mechanisms are essential for immunotherapeutic effi-
cacy. Listeria monocytogenes (Lm)-listeriolysin O (LLO)
immunotherapies have shown to both generate antigen-
specific T-cell responses and neutralize cells that protect
the tumor microenvironment. ADXS31-142 is a live atte-
nuated Lm-LLO immunotherapy designed to target the
prostate-specific antigen (PSA) and bioengineered to
secrete an antigen-adjuvant fusion protein, consisting of
a truncated fragment of the LLO fused to human PSA.
Programmed death receptor 1 (PD-1) is a cell surface
protein receptor central to T-cell immunity inhibition.
Pembrolizumab is a humanized monoclonal antibody
that binds to the PD-1 receptor, blocking interaction
with PD-1 ligands and thereby inhibiting tumor immune
evasion mechanisms. The combination of an Lm-LLO
immunotherapy with an anti-PD-1 antibody has shown
synergistic antitumor activity in preclinical studies.
Methods
This is a Phase I-II, open-label, multicenter, nonrando-
mized, 2-part study (NCT02325557) in patients with
mCRPC. Part A is a dose escalation of monotherapy
ADXS31-142, followed by Part B, a dose escalation of
ADXS31-142 plus pembrolizumab; Part B is followed by
a dose-expansion cohort. Primary objectives are to eval-
uate the safety and tolerability of ADXS31-142 alone
and in combination with pembrolizumab, and establish
the ADXS31-142 recommended Phase II dose (RP2D)
for monotherapy and combination therapy. Secondary
objectives include evaluation of antitumor activity and
progression-free survival. Male patients (≥18 years) with
progressive mCRPC (≤3 prior systemic treatment regi-
mens), on androgen deprivation therapy, and with an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–1 are eligible. Each dose-determining
part will enroll up to 21 patients. ADXS31-142 and
pembrolizumab (200 mg) are administered once every 3
weeks in a 12-week treatment cycle, with ADXS31-142
administration limited to weeks 1, 4, and 7. ADXS31-142
dose-escalations (up to a maximum of 1×1010 colony-
forming units [CFU]) and de-escalations are done
according to predefined dose-limiting toxicity criteria by
applying the modified toxicity probability interval design.
In Part A, the starting ADXS31-142 dose is 1×109 CFU,
and in Part B is either 1 level below the RP2D established
for monotherapy or 1×109 CFU, if this was the maximum
tolerated dose for monotherapy. Once the ADXS31-142
RP2D for combination with pembrolizumab is deter-
mined, the expansion cohort will open for enrollment.
A total of 30 patients are planned for treatment at the
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